Belmora has petitioned the Fourth Circuit to reconsider its decision that Bayer did not need to use the Flanax mark in the US to sue under the Lanham Act. Belmora says the court “appeared to be motivated by a sense of ethical outrage”
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Daniel Tarr explains why returning to his former firm could help him establish his personal brand, and predicts what’s on the horizon for AI litigation
A call to reinstate the European Commission's controversial SEP proposal and a trademark row involving Stanley cups were also among the top talking points